Royalty Pharma Drops $8B Hostile Bid For Elan
New York-based Royalty had made its offer conditional on Elan shareholders rejecting all proposals at a meeting Monday, including a $200 million stock buyback and three acquisitions that together would have set Elan on a new, independent path.
But investors approved one of the four resolutions, the share buyback, by a slim margin. Royalty's last...
To view the full article, register now.